Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: Effect of magnesium chloride.
Int J Pharm · 2018
Last updated 2026-05-28A study in rats compared two nasal sprays containing the GLP-1 drug exenatide, one with magnesium chloride and one with calcium chloride. The magnesium chloride version took over 110 minutes to turn into a gel at body temperature, while the calcium chloride version gelled in 8 to 20 minutes. The magnesium chloride spray also improved the drug's movement across cell layers, increased its presence in target organs, and raised its overall effectiveness compared to the calcium chloride version. Both sprays reduced food intake and body weight in high-fat-fed rats within ten days.
AI summary of the abstract below.
| Journal | Int J Pharm, 2018 |
|---|---|
| Citations | 18 |
| Relative citation ratio | 0.93 |
| NIH percentile | 48 |
| Molecules | exenatide |
Abstract
The aim of this research was to evaluate the potential of two chitosan (CS)-based hydrogel systems for nasal delivery of exenatide (EXT) in rats. Both of the EXT-loaded CS/glycerophosphate (GP)/CaCl (EXT/CS/GP/CaCl) and EXT/CS/GP/MgCl hydrogel systems had similar in vitro release profiles. However, a difference in metal salt surprisingly resulted in multifaceted differences between the two hydrogel systems, such as EXT stability, gelation time, transepithelial transport, biodistribution and pharmacokinetics. The gelation time of the EXT/CS/GP/MgCl hydrogel (more than 110 min) at 37 °C was much longer than that of the EXT/CS/GP/CaCl hydrogel (8.0-20.4 min). Transepithelial transport analysis showed that the CS/GP/MgCl hydrogel enhanced EXT transport across the Calu-3 cell monolayers more than the CS/GP/CaCl hydrogel (P < 0.05). After nasal administration in the rats, the EXT/CS/GP/MgCl hydrogel increased the distribution of EXT in the targeting organs and the relative bioavailability of EXT in the rats more than the EXT/CS/GP/CaCl hydrogel. Moreover, both EXT/CS/GP/salt hydrogel formulation treatments in high-fat-fed rats significantly decreased food intake and body weight relative to the EXT solution within ten days (P < 0.05). The aforementioned results suggest that the EXT/CS/GP/MgCl hydrogel formulation is more suitable to be used as a nasally delivered EXT formulation for the treatment of weight loss.
Verbatim abstract via PubMed 30389472 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.